Trial reportHaematologica2013
Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients.
Trial report in Haematologica, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 41 citations in OpenAlex.
- Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF-CC) in Subjects With Severe Hemophilia A.Clinical and translational science · 2018Trial
- How do we optimally utilize factor concentrates in persons with hemophilia?Hematology. American Society of Hematology. Education Program · 2021Review
- Evidence-Based Minireview: For overweight or obese persons with hemophilia A, should factor VIII dosing be based on ideal or actual body weight?Hematology. American Society of Hematology. Education Program · 2021Review
- Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice.Blood advances · 2021Review
- Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database.Journal of thrombosis and haemostasis : JTH · 2021Article
- Impact of extreme weight loss on factor VIII concentrate pharmacokinetics in haemophilia.BMJ case reports · 2021Article
- Stability of Turoctocog Alfa, a Recombinant Factor VIII Product, during Continuous Infusion In Vitro.TH open : companion journal to thrombosis and haemostasis · 2020Article
- The Authors Respond.Journal of managed care & specialty pharmacy · 2020Article
- Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach.Clinical pharmacokinetics · 2020Article
- Pharmacokinetics in routine haemophilia clinical practice: rationale and modalities-a practical review.Therapeutic advances in hematology · 2020Review
- Pharmacokinetic-guided dosing of factor VIII concentrate in a morbidly obese severe haemophilia A patient undergoing orthopaedic surgery.BMJ case reports · 2019Article
- Evaluation of high-fat high-fructose diet treatment in factor VIII (coagulation factor)-deficient mouse model.International journal of experimental pathology · 2018Article
- A case report of acute inferior myocardial infarction in a patient with severe hemophilia A after recombinant factor VIII infusion.Medicine · 2017Article
- Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis.Pharmaceutics · 2017Article
- Perioperative management of hemophilia patients receiving total hip and knee arthroplasty: a complication report of two cases.Therapeutics and clinical risk management · 2015Article
- The health and economic burden of haemophilia in Belgium: a rare, expensive and challenging disease.Orphanet journal of rare diseases · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since 1981, the number of factor VIII units to infuse into patients with hemophilia A in order to achieve adequate circulating factor VIII levels has been calculated using the formula: [body weight(kg)× desired factor VIII increase(%)]/2, assuming a factor VIII recovery value of 2 for all patients. This study's aim was to evaluate the impact of several morphometric parameters and various coagulation factor concentrates on factor VIII recovery.The analysis included 201 hemophilia A adults (>18 years of age) who were carefully selected from eight pharmacokinetic clinical trials using three recombinant factor VIII concentrates (Advate®, Kogenate® FS, or ReFactoAF®/Xyntha®). Regression tree analysis was used to identify factor VIII recovery predictors. The median factor VIII recovery was 2.16 for all patients. Using regression tree analysis, patients were separated into three groups on the basis of body mass index: below 20.3 kg/m(2), between 20.3 and 29.5 kg/m(2), and 29.6 kg/m(2) or more. Each group had a significantly different median factor VIII recovery (P<0.001): 1.60, 2.14, and 2.70, respectively. The type of coagulation factor concentrate had no influence on recovery in the regression tree. In conclusion, factor VIII dosing should be adapted to underweight and overweight patients, as a factor VIII recovery of 2 does not apply to these patients. Ideal body weight should be considered instead of actual body weight in the dose calculations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.